Noom has finalized its acquisition of Tailor Made Compounding (TMC), a licensed 503A pharmacy operating across 46 states, marking its first major acquisition and a strategic step into broader preventive care and healthy aging services. The transaction reflects Noom’s effort to integrate pharmaceutical capabilities into its behavior change platform, expanding beyond its core focus on weight management.
The addition of TMC enables Noom to incorporate a wider range of clinically appropriate therapies into its programs. This includes peptide-based treatments such as sermorelin and interventions like NAD+, aligning with increasing demand for personalized and preventive healthcare solutions. The acquisition also supports Noom’s ambition to address conditions beyond weight and hormonal health, positioning its platform within a broader continuum of care.
TMC brings established infrastructure, including sterile and non-sterile compounding capabilities, and serves more than 400 clinics alongside multiple telehealth partners. Its formulary spans men’s and women’s health, supplements, IV therapy, and other therapeutic categories, providing Noom with operational scale to support diversified treatment offerings.
Geoff Cook, CEO of Noom, stated, “Weight health is the entry point to preventive care – and foundational to healthy aging. But it’s not the end point. This acquisition continues Noom's expansion into healthy aging, supporting Noom's mission to empower everyone, everywhere to live better longer – every day. With the acquisition, we plan to broaden our formulary to include peptide-based therapies, like sermorelin, and healthy aging interventions, like NAD+, as we further expand the conditions we serve beyond weight and hormonal health.”
Cook further emphasized integration of behavioral and clinical approaches, noting, “By pairing sustainable behavior change with prescription-grade catalysts, we make lasting change feel easy. TMC produces those catalysts. By bringing this capability in-house, we’re building the infrastructure to scale proactive care responsibly, grounded in quality, compliance, and long-term outcomes.”
Tailor Made Compounding will continue operating as a wholly owned subsidiary under CEO Ross Jordan. The company recently expanded its facilities to over 40,000 square feet, incorporating advanced environmental controls and systems aligned with evolving regulatory standards.
Jordan added, “By joining Noom, we can integrate those therapies into a proven behavior-change platform focused on long-term outcomes. With medicine and habit science working together, we can support a healthcare ecosystem built for individualized care and lasting outcomes.”
Noom expects to complete integration and expand its healthy aging offerings later this year.
Click here for the original news story.